Aarhus Universitets segl

Jens Christian Jensenius

MAp19, the alternative splice product of the MASP2 gene

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Standard

MAp19, the alternative splice product of the MASP2 gene. / Degn, Søren Egedal; Thiel, Steffen; Nielsen, Ole et al.
I: Journal of Immunological Methods, Bind 373, Nr. 1-2, 2011, s. 89-101.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Harvard

Degn, SE, Thiel, S, Nielsen, O, Hansen, AG, Steffensen, R & Jensenius, JC 2011, 'MAp19, the alternative splice product of the MASP2 gene', Journal of Immunological Methods, bind 373, nr. 1-2, s. 89-101. https://doi.org/10.1016/j.jim.2011.08.006

APA

CBE

MLA

Vancouver

Degn SE, Thiel S, Nielsen O, Hansen AG, Steffensen R, Jensenius JC. MAp19, the alternative splice product of the MASP2 gene. Journal of Immunological Methods. 2011;373(1-2):89-101. doi: 10.1016/j.jim.2011.08.006

Author

Degn, Søren Egedal ; Thiel, Steffen ; Nielsen, Ole et al. / MAp19, the alternative splice product of the MASP2 gene. I: Journal of Immunological Methods. 2011 ; Bind 373, Nr. 1-2. s. 89-101.

Bibtex

@article{24b21042a58542e482606ccd06ee2f58,
title = "MAp19, the alternative splice product of the MASP2 gene",
abstract = "The lectin pathway of complement is a central part of innate immunity, but as a powerful inducer of inflammation it needs to be tightly controlled. The MASP2 gene encodes two proteins, MASP-2 and MAp19. MASP-2 is the serine protease responsible for lectin pathway activation. The smaller alternative splice product, MAp19, lacks a catalytic domain but retains two of three domains involved in association with the pattern-recognition molecules (PRMs): mannan-binding lectin (MBL), H-ficolin, L-ficolin and M-ficolin. MAp19 reportedly acts as a competitive inhibitor of MASP-2-mediated complement activation. In light of a ten times lower affinity of MAp19, versus MASP-2, for association with the PRMs, much higher serum concentrations of MAp19 than MASP-2 would be required for MAp19 to exert such an inhibitory activity. Just four amino acid residues distinguish MAp19 from MASP-2, and these are conserved between man, mouse and rat. Nonetheless we generated monoclonal rat anti-MAp19 antibodies and established a quantitative assay. We found the concentration of MAp19 in serum to be 217 ng/ml, i.e., 11nM, comparable to the 7 nM of MASP-2. In serum all MASP-2, but only a minor fraction of MAp19, was associated with PRMs. In contrast to previous reports we found that MAp19 could not compete with MASP-2 for binding to MBL, nor could it inhibit MASP-2-mediated complement activation. Immunohistochemical analyses combined with qRT-PCR revealed that both MAp19 and MASP-2 were mainly expressed in hepatocytes. High levels of MAp19 were found in urine, where MASP-2 was absent.",
keywords = "Alternative Splicing, Animals, Antibodies, Monoclonal, Antibody Affinity, Blotting, Western, Cytoplasm, Gene Expression Profiling, HEK293 Cells, Hepatocytes, Humans, Hybridomas, Immunohistochemistry, Kidney, Lectins, Macrophages, Alveolar, Mannose-Binding Lectin, Mannose-Binding Protein-Associated Serine Proteases, Mice, Protein Binding, Protein Isoforms, Rats, Reverse Transcriptase Polymerase Chain Reaction",
author = "Degn, {S{\o}ren Egedal} and Steffen Thiel and Ole Nielsen and Hansen, {Annette G} and Rudi Steffensen and Jensenius, {Jens C}",
note = "Copyright {\textcopyright} 2011 Elsevier B.V. All rights reserved.",
year = "2011",
doi = "10.1016/j.jim.2011.08.006",
language = "English",
volume = "373",
pages = "89--101",
journal = "Journal of Immunological Methods",
issn = "0022-1759",
publisher = "Elsevier BV",
number = "1-2",

}

RIS

TY - JOUR

T1 - MAp19, the alternative splice product of the MASP2 gene

AU - Degn, Søren Egedal

AU - Thiel, Steffen

AU - Nielsen, Ole

AU - Hansen, Annette G

AU - Steffensen, Rudi

AU - Jensenius, Jens C

N1 - Copyright © 2011 Elsevier B.V. All rights reserved.

PY - 2011

Y1 - 2011

N2 - The lectin pathway of complement is a central part of innate immunity, but as a powerful inducer of inflammation it needs to be tightly controlled. The MASP2 gene encodes two proteins, MASP-2 and MAp19. MASP-2 is the serine protease responsible for lectin pathway activation. The smaller alternative splice product, MAp19, lacks a catalytic domain but retains two of three domains involved in association with the pattern-recognition molecules (PRMs): mannan-binding lectin (MBL), H-ficolin, L-ficolin and M-ficolin. MAp19 reportedly acts as a competitive inhibitor of MASP-2-mediated complement activation. In light of a ten times lower affinity of MAp19, versus MASP-2, for association with the PRMs, much higher serum concentrations of MAp19 than MASP-2 would be required for MAp19 to exert such an inhibitory activity. Just four amino acid residues distinguish MAp19 from MASP-2, and these are conserved between man, mouse and rat. Nonetheless we generated monoclonal rat anti-MAp19 antibodies and established a quantitative assay. We found the concentration of MAp19 in serum to be 217 ng/ml, i.e., 11nM, comparable to the 7 nM of MASP-2. In serum all MASP-2, but only a minor fraction of MAp19, was associated with PRMs. In contrast to previous reports we found that MAp19 could not compete with MASP-2 for binding to MBL, nor could it inhibit MASP-2-mediated complement activation. Immunohistochemical analyses combined with qRT-PCR revealed that both MAp19 and MASP-2 were mainly expressed in hepatocytes. High levels of MAp19 were found in urine, where MASP-2 was absent.

AB - The lectin pathway of complement is a central part of innate immunity, but as a powerful inducer of inflammation it needs to be tightly controlled. The MASP2 gene encodes two proteins, MASP-2 and MAp19. MASP-2 is the serine protease responsible for lectin pathway activation. The smaller alternative splice product, MAp19, lacks a catalytic domain but retains two of three domains involved in association with the pattern-recognition molecules (PRMs): mannan-binding lectin (MBL), H-ficolin, L-ficolin and M-ficolin. MAp19 reportedly acts as a competitive inhibitor of MASP-2-mediated complement activation. In light of a ten times lower affinity of MAp19, versus MASP-2, for association with the PRMs, much higher serum concentrations of MAp19 than MASP-2 would be required for MAp19 to exert such an inhibitory activity. Just four amino acid residues distinguish MAp19 from MASP-2, and these are conserved between man, mouse and rat. Nonetheless we generated monoclonal rat anti-MAp19 antibodies and established a quantitative assay. We found the concentration of MAp19 in serum to be 217 ng/ml, i.e., 11nM, comparable to the 7 nM of MASP-2. In serum all MASP-2, but only a minor fraction of MAp19, was associated with PRMs. In contrast to previous reports we found that MAp19 could not compete with MASP-2 for binding to MBL, nor could it inhibit MASP-2-mediated complement activation. Immunohistochemical analyses combined with qRT-PCR revealed that both MAp19 and MASP-2 were mainly expressed in hepatocytes. High levels of MAp19 were found in urine, where MASP-2 was absent.

KW - Alternative Splicing

KW - Animals

KW - Antibodies, Monoclonal

KW - Antibody Affinity

KW - Blotting, Western

KW - Cytoplasm

KW - Gene Expression Profiling

KW - HEK293 Cells

KW - Hepatocytes

KW - Humans

KW - Hybridomas

KW - Immunohistochemistry

KW - Kidney

KW - Lectins

KW - Macrophages, Alveolar

KW - Mannose-Binding Lectin

KW - Mannose-Binding Protein-Associated Serine Proteases

KW - Mice

KW - Protein Binding

KW - Protein Isoforms

KW - Rats

KW - Reverse Transcriptase Polymerase Chain Reaction

U2 - 10.1016/j.jim.2011.08.006

DO - 10.1016/j.jim.2011.08.006

M3 - Journal article

C2 - 21871896

VL - 373

SP - 89

EP - 101

JO - Journal of Immunological Methods

JF - Journal of Immunological Methods

SN - 0022-1759

IS - 1-2

ER -